Vanguard Group Inc. Has $36.56 Million Stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Vanguard Group Inc. lifted its position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 3.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,464,952 shares of the company's stock after acquiring an additional 115,656 shares during the quarter. Vanguard Group Inc. owned 3.57% of ARS Pharmaceuticals worth $36,555,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. LPL Financial LLC lifted its holdings in ARS Pharmaceuticals by 11.4% in the fourth quarter. LPL Financial LLC now owns 21,408 shares of the company's stock worth $226,000 after acquiring an additional 2,190 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in ARS Pharmaceuticals during the 4th quarter valued at approximately $73,000. Sei Investments Co. bought a new position in ARS Pharmaceuticals during the 4th quarter worth $1,142,000. Teacher Retirement System of Texas acquired a new stake in ARS Pharmaceuticals in the fourth quarter worth $122,000. Finally, Intech Investment Management LLC lifted its stake in ARS Pharmaceuticals by 85.2% in the fourth quarter. Intech Investment Management LLC now owns 30,545 shares of the company's stock valued at $322,000 after buying an additional 14,051 shares during the last quarter. 68.16% of the stock is currently owned by institutional investors.

ARS Pharmaceuticals Price Performance

SPRY remained flat at $14.88 during trading on Friday. The company's stock had a trading volume of 1,550,196 shares, compared to its average volume of 1,153,076. The stock has a fifty day simple moving average of $12.27 and a 200 day simple moving average of $13.06. The stock has a market cap of $1.46 billion, a price-to-earnings ratio of -29.18 and a beta of 0.86. ARS Pharmaceuticals, Inc. has a 12-month low of $7.55 and a 12-month high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.56. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $15.46 million. As a group, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Eric Karas sold 10,000 shares of the stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the transaction, the insider now owns 7,696 shares in the company, valued at $107,744. This trade represents a 56.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Laura Shawver sold 50,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $12.31, for a total value of $615,500.00. Following the sale, the director now owns 210,346 shares in the company, valued at approximately $2,589,359.26. The trade was a 19.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 159,602 shares of company stock worth $1,926,541. Corporate insiders own 40.10% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on SPRY shares. Raymond James increased their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a "strong-buy" rating in a report on Tuesday, January 14th. William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners increased their price objective on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, January 13th. Scotiabank assumed coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 target price on the stock. Finally, Oppenheimer started coverage on ARS Pharmaceuticals in a research report on Monday, February 10th. They set an "outperform" rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $31.00.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.